| Autor: |
Platzbecker U; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de., Santini V; MDS Unit, AOU Careggi, University of Florence, Florence, Italy., Komrokji RS; Moffitt Cancer Center, Tampa, FL, USA., Zeidan AM; Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Buckstein R; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Miteva D; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland., Keeperman K; Bristol Myers Squibb, Princeton, NJ, USA., Holot N; Bristol Myers Squibb, Princeton, NJ, USA., Nadal JA; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland., Lai Y; Bristol Myers Squibb, Princeton, NJ, USA., Vodala S; Bristol Myers Squibb, Princeton, NJ, USA., Rosettani B; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland., Giuseppi AC; Bristol Myers Squibb, Princeton, NJ, USA., Yucel A; Bristol Myers Squibb, Princeton, NJ, USA., Fenaux P; Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris, France. |
Full text from SpringerLink